Heartflow, Inc. (NASDAQ:HTFL) Given Average Rating of “Moderate Buy” by Analysts

Heartflow, Inc. (NASDAQ:HTFL) has been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $37.00.

HTFL has been the subject of a number of research analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Canaccord Genuity Group dropped their price target on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Wells Fargo & Company lifted their price target on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Finally, William Blair initiated coverage on shares of Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating for the company.

Insider Buying and Selling

In other Heartflow news, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of Heartflow stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $29.23, for a total value of $27,732,167.11. Following the completion of the transaction, the insider owned 8,448,158 shares of the company’s stock, valued at $246,939,658.34. The trade was a 10.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction on Monday, May 11th. The stock was sold at an average price of $29.12, for a total transaction of $657,005.44. Following the completion of the transaction, the chief executive officer directly owned 519,397 shares of the company’s stock, valued at approximately $15,124,840.64. This represents a 4.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,193,134 shares of company stock worth $63,909,059. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Heartflow

A number of hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Heartflow during the fourth quarter valued at $27,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow during the fourth quarter valued at $45,000. Essential Partners LLC acquired a new position in shares of Heartflow during the first quarter valued at $57,000. Legal & General Group Plc acquired a new position in shares of Heartflow during the third quarter valued at $59,000. Finally, Strs Ohio acquired a new position in shares of Heartflow during the fourth quarter valued at $99,000.

Heartflow Stock Performance

NASDAQ HTFL opened at $28.45 on Thursday. Heartflow has a one year low of $20.13 and a one year high of $41.22. The company’s 50 day moving average price is $28.81 and its 200 day moving average price is $28.29. The firm has a market capitalization of $2.45 billion and a price-to-earnings ratio of -9.15.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.08. The business had revenue of $52.59 million during the quarter. The business’s revenue for the quarter was up 41.3% on a year-over-year basis. Sell-side analysts forecast that Heartflow will post -0.82 EPS for the current fiscal year.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.